Elucid’s Next-Generation Plaque Analysis and FFR_CT Technology to be Featured on 2022 AHA Scientific Sessions Program

Nov 4, 2022 | Press Releases

BOSTON – November 4, 2022 – Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American...

Elucid Appoints Dr. Michael Lesh to Board of Directors

Nov 3, 2022 | Press Releases

BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors.  ...

Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer

Jul 26, 2022 | Press Releases

BOSTON – July 26, 2022 – Elucid, a novel non-invasive software company providing physicians with AI-powered imaging to characterize cardiovascular disease, is pleased to announce that Todd C. Villines, MD, is joining the company as Chief Medical Officer. Dr. Villines...

Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis

Jun 23, 2022 | Press Releases

BOSTON – June 22, 2022 – Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round.  The round was led by an undisclosed strategic...

Expert Clinical Panel

Sep 24, 2021 | In the News

Using CT Angiography to Categorize & Stratify Risk in Patients with Subclinical to Unstable Coronary Artery Disease Gregg Stone, MD; Ron Blankstein, MD; Renu Virmani, MD; Joe Schoepf, MD; Tony Das, MD